EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

A Mega-Analysis of Anti-Müllerian Hormone Levels in Female Childhood Cancer Survivors Based on Treatment Risk, Time since Treatment, and Pubertal Status

Jacqueline C Yano Maher iD, Allison Kumnick, Ninet Sinaii, H Irene Su, Katherine E Cameron, Sobenna A George, Clarissa Gracia, Lillian R Meacham, Veronica Gomez-Lobo

Journal of Adolescent and Young Adult Oncology · 01.04.2025 · 14 (2) · 160-171

DOI: 10.1089/jayao.2024.0093 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Adolescent and Young Adult Oncology, online erschienen am 02.04.2025. Verfasst von Jacqueline C Yano Maher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Anti-Mullerian Hormone, Cancer Survivors, Neoplasms, Puberty. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Female childhood cancer survivors (CCSs) risk infertility due to gonadotoxic chemotherapy/radiation. Anti-Müllerian hormone (AMH) helps evaluate ovarian reserve, and the 2020 Oncofertility Pediatric Initiative Network (O-PIN) risk stratification is utilized to counsel risk of gonadal dysfunction/infertility. This study analyzed how AMH levels after cancer treatment differ with age and correlate AMH with O-PIN risk level and clinical outcomes.

Methods

A literature review and mega-analysis of individual patient data were performed. Females ages 0–20 years at the time of cancer diagnosis with AMH values post-treatment were included. AMH outcomes were compared by O-PIN risk stratification, age at diagnosis, cyclophosphamide equivalent dose (CED), and hematopoietic stem cell transplant (HSCT). Multivariable random effects mixed models correlated AMH with diminished ovarian reserve (DOR), premature ovarian insufficiency (POI), and pregnancy.

Results

In 13 studies with 608 CCSs, the median age (years) at diagnosis was 12.0 (interquartile range [IQR] 5.2–16.2) and 21.1 (IQR 17.1–30.0) at AMH measurement. AMH values were higher with time since treatment and correlated with the O-PIN risk level. Patients with HSCT had very low/undetectable AMH levels regardless of CED; when stratified by CED, AMH levels were lower if treated peripubertally or older. AMH was detectable in 54% (34/63) of patients with POI on hormone replacement. Pregnancy did not correspond to the gonadotoxicity risk level ( p = 0.70).

Conclusion

This study supports utilizing the O-PIN risk stratification system in estimating risk of DOR in CCSs and its categorization by pubertal status. AMH levels may return over time even after receiving the highest risk therapy. These findings may help counsel cancer patients pre- and post-therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Mullerian HormoneCancer SurvivorsNeoplasmsPubertyAdolescentAdultChildChild, PreschoolFemaleHumansInfantInfant, NewbornYoung AdultOvarian Reserve

Stichwörter der Autor:innen

anti-Müllerian hormonechildhood cancer survivorsdiminished ovarian reservegonandotoxicitypremature ovarian insufficiency

Substanzen

Anti-Mullerian Hormone

Autor:innen und Institutionen

  • Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
  • Department of Obstetrics and Gynecology, Medstar Washington Hospital Center, Washington, District of Columbia, USA.
  • Biostatistics and Clinical Epidemiology Service, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
  • Department of Obstetrics, Gynecology and Reproductive Sciences and Moores Cancer Center, University of California, San Diego, La Jolla, California, USA.
  • Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Jacqueline C Yano Maher

Förderung

  • NICHD NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Yano Maher, J. C., Kumnick, A., Sinaii, N., Su, H. I., Cameron, K. E., George, S. A., Gracia, C., Meacham, L. R., & Gomez-Lobo, V. (2025). A Mega-Analysis of Anti-Müllerian Hormone Levels in Female Childhood Cancer Survivors Based on Treatment Risk, Time since Treatment, and Pubertal Status. Journal of Adolescent and Young Adult Oncology, 14(2), 160-171. https://doi.org/10.1089/jayao.2024.0093

Vancouver

Yano Maher JC, Kumnick A, Sinaii N, Su HI, Cameron KE, George SA, et al. A Mega-Analysis of Anti-Müllerian Hormone Levels in Female Childhood Cancer Survivors Based on Treatment Risk, Time since Treatment, and Pubertal Status. Journal of Adolescent and Young Adult Oncology. 2025;14(2):160-171. doi:10.1089/jayao.2024.0093

BibTeX
@article{YanoMaher2025,
  author = {Yano Maher, Jacqueline C and Kumnick, Allison and Sinaii, Ninet and Su, H Irene and Cameron, Katherine E and George, Sobenna A and Gracia, Clarissa and Meacham, Lillian R and Gomez-Lobo, Veronica},
  title = {A Mega-Analysis of Anti-Müllerian Hormone Levels in Female Childhood Cancer Survivors Based on Treatment Risk, Time since Treatment, and Pubertal Status},
  journal = {Journal of Adolescent and Young Adult Oncology},
  year = {2025},
  volume = {14},
  number = {2},
  pages = {160--171},
  doi = {10.1089/jayao.2024.0093}
}
Kostenlos starten →